secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001159036-25-000061
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme CFO Nicole LaBrosse to depart by March 30, 2026 under transition agreement
--------------------------------------------------------------------------------

- CFO Nicole LaBrosse will remain until new CFO is hired or March 30, 2026, whichever comes first.
- Transition agreement provides 120% target bonus for 2025, severance equal to base salary plus pro-rated 2026 bonus.
- Equity awards vesting through February 28, 2026 will accelerate; option exercise period extended to one year post-separation.
- If a Change in Control occurs within one year after separation, unvested options will fully vest.
- COBRA coverage premiums paid for one year; agreement filed with 2025 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000061/0001159036-25-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000061/halo-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer